Oncopeptides announces the Nomination Committee
Stockholm – November 21, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the composition of the Nomination Committee has been established.
According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2026 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2025 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.
The Nomination Committee in respect of the annual general meeting 2026 consists of the following persons who together represent approximately 20 percent of the number of shares and votes in the company based on the shareholder information at end of September 2025.
- Staffan Lindstrand, appointed by HealthCap VI L.P.
- Jonas Brambeck, appointed by Jakob Lindberg
- Anna Henricsson appointed by Handelsbanken Funds
- Per Wold-Olsen, the Chairman of the Board
The Nomination Committee’s proposals will be presented in the Notice to the annual general meeting 2026 and on Oncopeptides’ website, www.oncopeptides.com.
Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to info@oncopeptides.com (subject “Nomination Committee”) or by letter posted to Oncopeptides AB (publ), Attn: Oncopeptides Nomination Committee, Luntmakargatan 46, SE-111 37 Stockholm, Sweden.
A proposal must reach the nomination committee no later than April 1, 2026, to be included in the notice to attend and the agenda for the annual general meeting.